Name: ACASTI PHARMA INC (ACST) Stock
Brand: ACASTI PHARMA INC
Rating: 7 (3 reviews)

ACST Latest News, Press Relases and Analysis

All

Press Releases

a year ago - By: Acasti Pharma, Inc.

Acasti Announces Corporate Name Change to Grace Therapeutics, Inc.

a year ago - By: Acasti Pharma, Inc.

Acasti Announces Completion of Patient Enrollment in Pivotal Phase 3 STRIVE-ON Safety Trial of GTX-104

a year ago - By: Virtual Investor Conferences - Mentions: NYSE APRE AEMD UNCY ...

Life Sciences Virtual Investor Forum Presentations Now Available for Online Viewing

a year ago - By: Virtual Investor Conferences - Mentions: VNRX APRE CHRO PLX ...

Life Sciences Virtual Investor Forum Agenda Announced for September 19th

a year ago - By: BusinessInsider

ACST Stock Earnings: Acasti Pharma Beats EPS for Q1 2025

a year ago - By: InvestorPlace

ACST Stock Earnings: Acasti Pharma Beats EPS for Q1 2025

a year ago - By: Acasti Pharma, Inc.

Acasti to Participate in the H.C. Wainwright 26th Annual Global Investment Conference

a year ago - By: Acasti Pharma, Inc.

Acasti Announces First Fiscal Quarter 2025 Financial Results, Provides Business Update

a year ago - By: Acasti Pharma, Inc.

Acasti Announces Achievement of 50% Enrollment in Pivotal Phase 3 STRIVE-ON Safety Trial

a year ago - By: BusinessInsider

ACST Stock Earnings: Acasti Pharma Beats EPS for Q4 2024

a year ago - By: InvestorPlace

ACST Stock Earnings: Acasti Pharma Beats EPS for Q4 2024

a year ago - By: Acasti Pharma, Inc.

Acasti Announces Year-End 2024 Financial Results, Provides Business Update

2 years ago - By: Acasti Pharma, Inc.

Acasti Announces Poster Detailing its GTX-104 STRIVE-ON Trial

2 years ago - By: Benzinga

Why Acasti Pharma (ACST) Stock Is Exploding Higher

2 years ago - By: Acasti Pharma Inc.

Acasti Pharma Announces 1-for-6 Reverse Stock Split

a year ago - By: InvestorPlace - Mentions: TNXP MNMD

Wall Street Favorites: 3 Penny Stocks With Strong Buy Ratings for June 2024

2 years ago - By: Acasti Pharma, Inc.

Acasti Pharma to Attend BIO International Convention 2024

2 years ago - By: InvestorPlace - Mentions: NVAX SNY ENTX KPTI

The Next Novavax? 3 Biopharma Stocks to Buy Before They Boom

2 years ago - By: Acasti Pharma, Inc.

Acasti Announces Third Fiscal Quarter 2024 Financial Results and Business Highlights

2 years ago - By: Benzinga - Mentions: CANO LICY RAMP MIMO ...

Why KeyCorp Shares Are Trading Lower By Over 5%? Here Are Other Stocks Moving In Thursday's Mid-Day Session

2 years ago - By: Acasti Pharma Inc.

Acasti Pharma Reports Fiscal Year 2023 Operational Results

2 years ago - By: Acasti Pharma, Inc.

Acasti to Participate in Upcoming San Francisco Investor Conferences in January 2024

2 years ago - By: Acasti Pharma, Inc.

Acasti Announces Second Quarter 2024 Financial Results and Business Highlights

2 years ago - By: Acasti Pharma, Inc.

Acasti Pharma to Host KOL Event on GTX-104: A Potential New Treatment Standard for Rare and Life-Threatening aneurysmal Subarachnoid Hemorrhage (aSAH)

2 years ago - By: Seeking Alpha

Acasti Pharma director discloses purchase of 676,371 shares (NASDAQ:ACST)

3 years ago - By: Acasti Pharma Inc.

Acasti Pharma Inc. Announces the Resignation of a Director

3 years ago - By: Acasti Pharma Inc.

Acasti Pharma Recognizes Rare Disease Day

2 years ago - By: Seeking Alpha

Acasti announces $7.5M private placement equity funding (NASDAQ:ACST)

2 years ago - By: Acasti Pharma, Inc.

Acasti Announces $7.5 Million Private Placement Equity Financing

2 years ago - By: Acasti Pharma, Inc.

Acasti Announces First Quarter 2024 Financial Results and Business Highlights

2 years ago - By: Seeking Alpha

Acasti Pharma announces 1-for-6 reverse stock split (NASDAQ:ACST)

2 years ago - By: Acasti Pharma Inc.

Acasti Announces Alignment with FDA on GTX-104 Pivotal Phase 3 Safety Trial Protocol and Confirms Planned Initiation of STRIVE-ON in aSAH Patients in Calendar Q4 2023

3 years ago - By: InvestorPlace - Mentions: ERYP CLRO MTEK MOBQ ...

Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Tuesday

3 years ago - By: Acasti Pharma Inc.

Acasti Successfully Submits Pivotal GTX-104 Phase 3 Safety Study Protocol with FDA and Implements Strategic Realignment Plan That Extends Projected Cash Runway Through Calendar Q2 2025

3 years ago - By: Acasti Pharma Inc.

Acasti to Proceed with Phase 3 Clinical Safety Study for GTX-104 Following FDA Feedback, and Upon Approval of the Full Study Protocol to be Submitted to the IND

3 years ago - By: InvestorPlace - Mentions: VORB GME DBD MMV ...

Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Wednesday

3 years ago - By: Acasti Pharma Inc.

ACASTI PHARMA INC (ACST) Stock News

ACST Latest News, Press Relases and Analysis

Acasti Announces Corporate Name Change to Grace Therapeutics, Inc.

Acasti Announces Completion of Patient Enrollment in Pivotal Phase 3 STRIVE-ON Safety Trial of GTX-104

Life Sciences Virtual Investor Forum Presentations Now Available for Online Viewing

Life Sciences Virtual Investor Forum Agenda Announced for September 19th

ACST Stock Earnings: Acasti Pharma Beats EPS for Q1 2025

ACST Stock Earnings: Acasti Pharma Beats EPS for Q1 2025

Acasti to Participate in the H.C. Wainwright 26th Annual Global Investment Conference

Acasti Announces First Fiscal Quarter 2025 Financial Results, Provides Business Update

Acasti Announces Achievement of 50% Enrollment in Pivotal Phase 3 STRIVE-ON Safety Trial

ACST Stock Earnings: Acasti Pharma Beats EPS for Q4 2024

ACST Stock Earnings: Acasti Pharma Beats EPS for Q4 2024

Acasti Announces Year-End 2024 Financial Results, Provides Business Update

Acasti Announces Poster Detailing its GTX-104 STRIVE-ON Trial

Why Acasti Pharma (ACST) Stock Is Exploding Higher

Acasti Pharma Announces 1-for-6 Reverse Stock Split

Wall Street Favorites: 3 Penny Stocks With Strong Buy Ratings for June 2024

Acasti Pharma to Attend BIO International Convention 2024

The Next Novavax? 3 Biopharma Stocks to Buy Before They Boom

Acasti Announces Third Fiscal Quarter 2024 Financial Results and Business Highlights

Why KeyCorp Shares Are Trading Lower By Over 5%? Here Are Other Stocks Moving In Thursday's Mid-Day Session

Acasti Pharma Reports Fiscal Year 2023 Operational Results

Acasti to Participate in Upcoming San Francisco Investor Conferences in January 2024

Acasti Announces Second Quarter 2024 Financial Results and Business Highlights

Acasti Pharma to Host KOL Event on GTX-104: A Potential New Treatment Standard for Rare and Life-Threatening aneurysmal Subarachnoid Hemorrhage (aSAH)

Acasti Pharma director discloses purchase of 676,371 shares (NASDAQ:ACST)

Acasti Pharma Inc. Announces the Resignation of a Director

Acasti Pharma Recognizes Rare Disease Day

Acasti announces $7.5M private placement equity funding (NASDAQ:ACST)

Acasti Announces $7.5 Million Private Placement Equity Financing

Acasti Announces First Quarter 2024 Financial Results and Business Highlights

Acasti Pharma announces 1-for-6 reverse stock split (NASDAQ:ACST)

Acasti Announces Alignment with FDA on GTX-104 Pivotal Phase 3 Safety Trial Protocol and Confirms Planned Initiation of STRIVE-ON in aSAH Patients in Calendar Q4 2023

Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Tuesday

Acasti Successfully Submits Pivotal GTX-104 Phase 3 Safety Study Protocol with FDA and Implements Strategic Realignment Plan That Extends Projected Cash Runway Through Calendar Q2 2025

Acasti to Proceed with Phase 3 Clinical Safety Study for GTX-104 Following FDA Feedback, and Upon Approval of the Full Study Protocol to be Submitted to the IND

Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Wednesday

Acasti Pharma Inc. Centralizes Marketplace for Shares on the Nasdaq with Voluntary Delisting from TSX Venture Exchange